SCHEMBL7140146

SCHEMBL7140146

OCc1[nH]c(-c2ccccc2)nc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.52
MAPK13 O15264 7/20 0.49
MAPK12 P53778 7/20 0.49
MAPK11 Q15759 7/20 0.49
MAPK14 Q16539 7/20 0.49
RAF1 P04049 3/20 0.49
MAPK9 P45984 1/20 0.49
POLB P06746 1/20 0.49
GCGR P47871 4/20 0.47
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
ALOX5 P09917 1/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9081383 0.85 BRAF (0.46) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL33656 0.81 GAA (0.43) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL33678 0.81 KDM4E (0.50) BRAFPOLBTP53MAPTALDH1A1
SCHEMBL11280088 0.80 KDM4E (0.58) BRAFPOLBALDH1A1HPGDCYP1A2
SCHEMBL29000682 0.80 MAPK14 (0.47) BRAFMAPK13MAPK12MAPK11MAPK14
Ammonia Solution, Strong SCHEMBL25300630 0.80 GAA (0.42) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL28104155 0.80 KDM4E (0.49) BRAFPOLBTP53MAPTALDH1A1
SCHEMBL649956 0.80 HPGD (0.45) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL9339022 0.77 SMPD3 (0.46) BRAFPOLBGCGRTP53MAPT
SCHEMBL468691 0.77 LTB4R (0.47) BRAFALDH1A1HPGDCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed